keyword
MENU ▼
Read by QxMD icon Read
search

Desvenlafaxine

keyword
https://www.readbyqxmd.com/read/28929323/what-type-and-dose-of-antidepressants-are-cancer-and-non-cancer-inpatients-being-prescribed-a-retrospective-case-control-study-at-an-australian-tertiary-hospital
#1
Saira Sanjida, Kelly Mulvogue, Joanne Shaw, Jeremy Couper, David Kissane, Sallie-Anne Pearson, Melanie A Price, Monika Janda
PURPOSE: Cancer patients are often prescribed antidepressants, but little data is available about whether the type and dose are similar to prescriptions to patients with other chronic diseases. This study compared the prescription practices of antidepressants to cancer and non-cancer inpatients at a major Australian tertiary hospital and assessed side effects and potential drug-drug interactions. METHODS: Inpatients diagnosed with cancer within the past 12 months and prescribed antidepressants were age and gender matched to inpatients with other chronic disease conditions...
September 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28888484/prediction-of-human-efficacious-antidepressant-doses-using-the-mouse-forced-swim-test
#2
Eunice Yuen, Steven Swanson, Jeffrey M Witkin
The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experiments were carried out on mice using four marketed antidepressants (citalopram, desipramine, bupropion, desvenlafaxine) in addition to ketamine, all with varying mechanisms of action...
September 6, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28827861/the-prospective-24-week-assessment-of-cost-efficacy-of-and-compliance-to-antidepressant-medications-in-a-rural-setting-pacecar-study
#3
T S Sathyanarayana Rao, J Shivanand Manohar, Rajesh Raman, M S Darshan, Abhinav Tandon, K N Karthik, N Saraswathi, Keya Das, G T Harsha, Swetha Patil Kunkeri, Chittaranjan Andrade
BACKGROUND: Anxiety and depression are common mental health disorders that are responsible for considerable societal burden. There are no data on cost-efficacy and medication compliance related to the treatment of these disorders in rural India. MATERIALS AND METHODS: All consenting adults (n = 455) diagnosed with generalized anxiety or (unipolar) depressive disorders in Suttur village, Karnataka, were treated with open-label fluoxetine (20-60 mg/day), sertraline (50-150 mg/day), escitalopram (10-20 mg/day), desvenlafaxine (50-150 mg/day), duloxetine (30-90 mg/day), amitriptyline (75-150 mg/day), or clomipramine (75-150 mg/day) in a structured, monotherapy dosing plan...
April 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28817491/speed-of-improvement-in-symptoms-of-depression-with-desvenlafaxine-50-mg-and-100-mg-compared-with-placebo-in-patients-with-major-depressive-disorder
#4
Martin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, Ellen Meier, Rita Prieto, Elizabeth Pappadopulos, Joan Mackell, Matthieu Boucher
PURPOSE/BACKGROUND: This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with desvenlafaxine versus placebo. METHODS: Data were pooled from 9 short-term, double-blind, placebo-controlled studies in adults with MDD randomly assigned to desvenlafaxine 50 mg/d, 100 mg/d, or placebo. A mixed-effects model for repeated-measures analysis of change from baseline score was used to determine the time point at which desvenlafaxine treatment groups separated from placebo on the 17-item Hamilton Rating Scale for Depression and psychosocial outcomes...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28803957/a-standardization-of-the-novelty-suppressed-feeding-test-protocol-in-rats
#5
Arantxa Blasco-Serra, Eva M González-Soler, Ana Cervera-Ferri, Vicent Teruel-Martí, Alfonso A Valverde-Navarro
Tests based on hyponeophagia phenomena are the most widely used to check the efficacy and efficiency of new-generation chronic antidepressant treatments. Even so, these tests lack strict consensus about their methodology, which reduces their validity, reproducibility and makes translatability difficult. Therefore, after an extensive literature review on this subject, we propose a methodological protocol for the Novelty-Suppressed Feeding Test to normalize this situation. Animals were induced to a reserpine-induced depression model and were then chronically treated with duloxetine, desvenlafaxine or vehicle...
August 10, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28763345/risk-of-hair-loss-with-different-antidepressants-a-comparative-retrospective-cohort-study
#6
Mahyar Etminan, Mohit Sodhi, Ric M Procyshyn, Michael Guo, Bruce C Carleton
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion, with sertraline the most commonly prescribed (N=190 227) and fluvoxamine (N=3010) the least prescribed...
July 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28763344/the-impact-of-fatigue-and-energy-on-work-functioning-and-impairment-in-patients-with-major-depressive-disorder-treated-with-desvenlafaxine
#7
David Sarfati, Vanessa C Evans, Edwin M Tam, Cindy Woo, Grant L Iverson, Lakshmi N Yatham, Raymond W Lam
Fatigue and low energy are cardinal symptoms of major depressive disorder (MDD) that have an impact on work functioning. Antidepressants with noradrenergic activity have been hypothesized to improve symptoms of fatigue and low energy. We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50-100 mg/day for 8 weeks...
July 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28725139/hybrid-polymeric-matrices-for-oral-modified-release-of-desvenlafaxine-succinate-tablets
#8
Wael Samy, Ayman Elnoby, Hanan M El-Gowelli, Nazik Elgindy
Purpose: Desvenlafaxine succinate (DSV) is a water soluble anti-depressant drug, which is rapidly absorbed after oral administration exaggerating its side effects. The current work aimed to prepare controllable release DSV matrix to reduce DSV side effects related to its initial burst. Methods: Fifteen DSV matrix formulations were prepared using different polymers, polymer/drug ratios and matrix excipients and characterized using Differential Scanning Calorimetry (DSC), infrared (IR) spectroscopy, water uptake and in vitro DSV release...
July 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28718346/effect-of-desvenlafaxine-50-mg-and-100-mg-on-energy-and-lassitude-in-patients-with-major-depressive-disorder-a-pooled-analysis
#9
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell, Matthieu Boucher
Nine randomized, double-blind, placebo-controlled studies of major depressive disorder were pooled to evaluate the effects of desvenlafaxine 50- and 100-mg/d on energy and lassitude in adults with major depressive disorder ( n=4279). Changes from baseline to endpoint in 17-item Hamilton Rating Scale for Depression (HAM-D17) Work and Activities, Retardation, and Somatic Symptoms General items, HAM-D17 psychomotor retardation factor, and Montgomery-Åsberg Depression Rating Scale Lassitude item were analyzed with a mixed model for repeated measures analysis of variance...
July 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28649145/do-ssris-and-snris-reduce-the-frequency-and-or-severity-of-hot-flashes-in-menopausal-women
#10
Chris Stubbs, Lisa Mattingly, Steven A Crawford, Elizabeth A Wickersham, Jessica L Brockhaus, Laine H McCarthy
CLINICAL QUESTION: In menopausal women who experience regular hot flashes, does treatment with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) reduce the frequency and/or severity of hot flashes? ANSWER: Yes. Review of the literature suggests that treatment with SSRIs or SNRIs reduces the frequency and severity of hot flashes in menopausal and post-menopausal women. Studies demonstrated that paroxetine (Paxil), citalopram (Celexa) and escitolapram (Lexapro) were the most effective SSRIs, and venlafaxine (Effexor) was the most effective first line SNRI, with desvenlafaxine as a second option...
May 2017: Journal of the Oklahoma State Medical Association
https://www.readbyqxmd.com/read/28605847/impact-of-on-site-small-and-large-scale-wastewater-treatment-facilities-on-levels-and-fate-of-pharmaceuticals-personal-care-products-artificial-sweeteners-pesticides-and-perfluoroalkyl-substances-in-recipient-waters
#11
Pablo Gago-Ferrero, Meritxell Gros, Lutz Ahrens, Karin Wiberg
One of the main risks associated with effluents from both wastewater treatment plants (WWTPs) and on-site sewage treatment facilities (OSSFs) is the release of micropollutants (MPs) in receiving water bodies. However, the impact of MPs present in the effluents of OSSFs in the aquatic environment has not been studied so far. The current study evaluates the impact of the effluents of OSSFs and small-to-large scale WWTPs on natural waters. The discharge of 74 MPs was assessed including pharmaceuticals, personal care products, pesticides, artificial sweeteners and perfluoroalkyl substances (PFASs)...
December 1, 2017: Science of the Total Environment
https://www.readbyqxmd.com/read/28465217/antidepressants-induce-autophagy-dependent-nlrp3-inflammasome-inhibition-in-major-depressive-disorder
#12
Elísabet Alcocer-Gómez, Nieves Casas-Barquero, Matthew R Williams, Samuel L Romero-Guillena, Diego Cañadas-Lozano, Pedro Bullón, José Antonio Sánchez-Alcazar, José M Navarro-Pando, Mario D Cordero
Major Depressive Disorder (MDD, ICD-10: F-33) is a prevalent illness in which the pathogenic mechanism remains elusive. Recently an important role has been attributed to neuro-inflammation, and specifically the NLRP3-inflammasome complex, in the pathogenesis of MDD. This suggests a key role for immunomodulation as a key pathway in the treatment of this disorder. This study evaluates the involvement of nine common antidepressants in the NLRP3-inflammasome complex (fluoxetine, paroxetine, mianserin, mirtazapine, venlafaxine, desvenlafaxine, amitriptyline, imipramine and agomelatine), both in in vitro THP-1 cells stimulated by ATP, and in a stress-induced depressive animal or MDD patients...
May 2, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28334528/why-prodrugs-and-propesticides-succeed
#13
REVIEW
John E Casida
What are the advantages of bioactivation in optimizing drugs and pesticides? Why are there so many prodrugs and propesticides? These questions are examined here by considering compounds selected on the basis of economic value or market success in 2015. The 100 major drugs and 90 major pesticides are divided into ones acting directly and those definitely or possibly requiring bioactivation. Established or candidate prodrugs accounted for 19% of the total drug sales, with corresponding values of 20, 37, and 17% for proinsecticides, proherbicides, and profungicides...
May 15, 2017: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/28250562/comparison-of-effect-of-antidepressants-on-psychomotor-functions
#14
Pranjali P Mendhe, Samidh P Shah, Mira K Desai, Minakshi N Parikh
OBJECTIVE: The comparison of the effect of antidepressants on psychomotor functions in patients with endogenous depression. MATERIALS AND METHODS: This prospective interventional study was carried out at a tertiary care teaching hospital on 95 literate patients with newly diagnosed endogenous depression matching inclusion and exclusion criteria. Patients were prescribed either desvenlafaxine (50 mg) or fluoxetine (40 mg) or sertraline (50 mg). Psychomotor functions were assessed by digit letter substitution, six letter cancellation, choice reaction time, hand steadiness and flicker fusion test at the baseline 1(st) month and 3(rd) month...
January 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/28229443/-desvenlafaxine-and-neuropathic-pain-additional-clinical-benefits-of-a-second-generation-serotonin-noradrenaline-reuptake-inhibitor
#15
REVIEW
A Alcantara-Montero
INTRODUCTION: Desvenlafaxine is the third antidepressant within the group of serotonin-norepinephrine reuptake inhibitors. The latest clinical practice guidelines consulted agree that tricyclic antidepressants, dual (venlafaxine/duloxetine) and gabapentin/pregabalin antiepileptics, are the first-line drugs in the treatment of neuropathic pain, being tramadol, lidocaine 5% patches and capsaicin 8% patches of second-line drugs, while strong opioids constitute a third line treatment. The interaction between the binomial pain and depression is very frequent, being the psychological complication more frequent in patients with chronic pain...
March 1, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28159109/multi-residue-determination-of-micropollutants-in-phragmites-australis-from-constructed-wetlands-using-microwave-assisted-extraction-and-ultra-high-performance-liquid-chromatography-tandem-mass-spectrometry
#16
Bruce Petrie, Benjamin D Smith, Jane Youdan, Ruth Barden, Barbara Kasprzyk-Hordern
In constructed wetlands micropollutants can be removed from water by phytoremediation. However, micropollutant uptake and metabolism by plants here is poorly understood due to the lack of good analytical approaches. Reported herein is the first methodology developed and validated for the multi-residue determination of 81 micropollutants (pharmaceuticals, personal care products and illicit drugs) in the emergent macrophyte Phragmites australis. The method involved extraction by microwave accelerated extraction (MAE), clean-up using off-line solid phase extraction and analysis by ultra-high-performance liquid chromatography tandem mass spectrometry...
March 22, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/28146000/efficacy-of-desvenlafaxine-compared-with-placebo-in-major-depressive-disorder-patients-by-age-group-and-severity-of-depression-at-baseline
#17
Daniel Mosca, Min Zhang, Rita Prieto, Matthieu Boucher
PURPOSE: This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS: Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term, placebo-controlled, major depressive disorder studies (N = 4279). Effects of age (18-40 years, >40 to <55 years, 55-<65 years, and ≥65 years) and baseline depression severity (mild, 17-item Hamilton Rating Scale for Depression total score [HAM-D17] ≤18; moderate, HAM-D17 >18 to <25; severe, HAM-D17 ≥25) on desvenlafaxine efficacy were assessed using analysis of covariance for continuous end points and logistic regression for categorical end points...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28079059/co-variation-of-peripheral-levels-of-mir-1202-and-brain-activity-and-connectivity-during-antidepressant-treatment
#18
Juan Pablo Lopez, Fabricio Pereira, Stéphane Richard-Devantoy, Marcelo Berlim, Eduardo Chachamovich, Laura M Fiori, Paola Niola, Gustavo Turecki, Fabrice Jollant
MicroRNAs are short non-coding molecules that play a major role in regulating gene expression. Peripheral levels of miR-1202 have been shown to predict and mediate antidepressant response. However, it is not clear to what extent these peripheral measures reflect central neural changes in vivo. We approached this problem with the combined use of peripheral miR-1202 measures and neuroimaging. At baseline and after 8 weeks of desvenlafaxine (50-100 mg die), 20 patients were scanned with 3T magnetic resonance imaging, first at rest then during the Go/NoGo task, a classical test of response inhibition...
September 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28074989/-antidepressants-agents-in-breast-cancer-patients-using-tamoxifen-review-of-basic-and-clinical-evidence
#19
REVIEW
María Elisa Irarrázaval O, Leonardo Gaete G
Tamoxifen (Tmf), is a standard of care for women with estrogen receptor positive (ER+) breast cancer. Endoxifen is a Tmf metabolite generated by cytochrome P450 2D6 (CYP2D6). Antidepressive agents (AD) are often prescribed to women with breast cancer not only for depression, but also for anxiety and hot flashes. Some AD are substrates or inhibitors of the Tmf metabolic pathway. Therefore there may be interactions when Tmf and AD are prescribed simultaneously. Oncologic protection afforded by Tmf may become less effective or null when AD are indicated, especially in poor metabolizing patients...
October 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28064115/do-social-functioning-and-symptoms-improve-with-continuation-antidepressant-treatment-of-persistent-depressive-disorder-an-observational-study
#20
David J Hellerstein, Kallio Hunnicutt-Ferguson, Jonathan W Stewart, Patrick J McGrath, Samantha Keller, Bradley S Peterson, Ying Chen
OBJECTIVE: To determine efficacy of continued treatment with the serotonin norepinephrine reuptake inhibitor duloxetine on symptom reduction and functional improvement in outpatients with dysthymia. METHOD: Fifty outpatients with DSM-IV-TR diagnosed dysthymia who had participated in a 10 week double-blind, placebo-controlled study of duloxetine received open treatment for three months. Nineteen duloxetine responders continued duloxetine, 24 patients initially treated with placebo started open duloxetine treatment, and 7 duloxetine non-responders were treated with desvenlafaxine or bupropion, selected by clinician choice...
December 20, 2016: Journal of Affective Disorders
keyword
keyword
48023
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"